Esperion Therapeutics Stock News

Esperion Therapeutics (ESPR) reports dismal first-quarter results as it misses estimates for earnings and sales. Stock down.

Analysts have provided the following ratings for Esperion Therapeutics (NASDAQ:ESPR) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 0 0 1 Somewhat Bullish 2 0 0

Esperion Therapeutics, Inc. (ESPR) CEO Timothy Mayleben on Q1 2021 Results - Earnings Call Transcript

– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price –

ANN ARBOR, Mich., April 26, 2021 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced that an investor group led by Oberland Capital Management LLC (Oberland Capital) agreed to pro

–  Esperion to Receive $30.0 Million Upfront and Up to $175.0 Million in Milestone Payments – –  Milestones from Partnership with Daiichi Sankyo Group Now Total Up to $1.1 Billion – –  D

ANN ARBOR, Mich., April 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2021 financial results after the close of the U.S. financial markets on Tuesd

- Results of bempedoic acid, ezetimibe and atorvastatin triple therapy study published in March issue of Atherosclerosis -

With the trading day halfway over, the broad markets were making yet another strong push.

Esperion's share price has bounced up and down during 2020 while its short interest skyrocketed.

Esperion Therapeutics (ESPR) reports dismal fourth-quarter results as it misses estimates for earnings and sales. Sales were hurt due to COVID-19.

Esperion Therapeutics, Inc. (ESPR) CEO Timothy Mayleben on Q4 2020 Results - Earnings Call Transcript

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -3.46% and -49.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the sto

Shares of Esperion Therapeutics (NASDAQ:ESPR) decreased after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 72.12% over the past year to ($3.89),

ANN ARBOR, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. financial ma